ArticleEuropean radiology2019
Multiparametric whole-body 3.0-T MRI in newly diagnosed intermediate- and high-risk prostate cancer: diagnostic accuracy and interobserver agreement for nodal and metastatic staging.
Article in European radiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06071195 (All-in-One Prostate Cancer Staging with MRI), which is not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
All-in-One Prostate Cancer Staging with MRI
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- The Role of Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Primary Staging of Newly Diagnosed Prostate Cancer: A Systematic Review of the Literature.European urology oncology · 2021Pooled it
- 5 T versus 3 T MRI for prostate cancer: an intra-individual prospective comparison of image quality and diagnostic performance.Prostate cancer and prostatic diseases · 2026Article
- Added Value of Whole-Body Diffusion-Weighted Imaging in Patients Undergoing Prostate-Specific Membrane Antigen Positron Emission Tomography.Journal of clinical medicine · 2025Article
- Review
- Reasons for Discordance betweenCancers · 2024Article
- Benefit and harm of lymphadenectomy in intermediate risk prostate cancer: comparison of five nomograms.BMC urology · 2023Article
- The role of MRI in prostate cancer: current and future directions.Magma (New York, N.Y.) · 2022Review
- The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer.Nature reviews. Urology · 2022Review
- Significance of pelvic lymph node dissection during radical prostatectomy in high-risk prostate cancer patients receiving neoadjuvant chemohormonal therapy.Scientific reports · 2022Article
- The role of MRI in the management of a prostate cancer patient with bone and lymph nodes metastases. A case report.Acta bio-medica : Atenei Parmensis · 2021Article
- Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine.European urology open science · 2021Article
- Prospective comparison ofEuropean journal of nuclear medicine and molecular imaging · 2021Article
- Repeatability and reproducibility of ADC measurements: a prospective multicenter whole-body-MRI study.European radiology · 2021Article
- The prevalence and locations of bone metastases using whole-body MRI in treatment-naïve intermediate- and high-risk prostate cancer.European radiology · 2021Article
- Comparison of PET/CT and MRI in the Diagnosis of Bone Metastasis in Prostate Cancer Patients: A Network Analysis of Diagnostic Studies.Frontiers in oncology · 2021Article
- Whole-body magnetic resonance imaging: technique, guidelines and key applications.Ecancermedicalscience · 2021Review
- Whole Body 3.0 T Magnetic Resonance Imaging in Lymphomas: Comparison of Different Sequence Combinations for Staging Hodgkin's and Diffuse Large B Cell Lymphomas.Journal of personalized medicine · 2020Article
- What's New for Clinical Whole-body MRI (WB-MRI) in the 21st Century.The British journal of radiology · 2020Review
- Whole-body magnetic resonance imaging (WB-MRI) reporting with the METastasis Reporting and Data System for Prostate Cancer (MET-RADS-P): inter-observer agreement between readers of different expertise levels.Cancer imaging : the official publication of the International Cancer Imaging Society · 2020Article
- Shortening the acquisition time of whole-body MRI: 3D T1 gradient echo Dixon vs fast spin echo for metastatic screening in prostate cancer.European radiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
objectivesTo determine the diagnostic accuracy and interobserver concordance of whole-body (WB)-MRI, vs.
methodsAn institutional review board approved prospective cohort study carried out between July 2012 and November 2015, whereby 56 men prospectively underwent 3.0-T multiparametric (mp)-WB-MRI in addition to BS (all patients) ±
resultsThe mean sensitivity/specificity of WB-MRI for N1 disease was 1.00/0.96 respectively, compared with 1.00/0.82 for
conclusionsWB-MRI provides high levels of diagnostic accuracy for both nodal and metastatic bone disease, with higher levels of sensitivity than BS for metastatic disease, and similar performance to KEY POINTS: • A whole-body MRI protocol comprising unenhanced mDixon and diffusion-weighted imaging provides high levels of diagnostic accuracy for the primary staging of intermediate- and high-risk prostate cancer. • The diagnostic accuracy of whole-body MRI is much higher than that of bone scintigraphy, as currently recommended for clinical use. • Staging using WB-MRI, rather than bone scintigraphy, could result in better patient stratification and treatment delivery than is currently provided to patients worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.